Preclinical News and Research

RSS
Vical announces issuance of US patent for HSV-2 vaccine

Vical announces issuance of US patent for HSV-2 vaccine

9 Feb 2011
Gentium completes Defibrotide clinical studies, plans to file for regulatory approval

Gentium completes Defibrotide clinical studies, plans to file for regulatory approval

9 Feb 2011
AMAG receives Health Canada Notice of Non-Compliance for Feraheme NDS

AMAG receives Health Canada Notice of Non-Compliance for Feraheme NDS

9 Feb 2011
Pervasis' Vascugel granted Fast Track review status for prevention of hemodialysis access failure in ESRD patients

Pervasis' Vascugel granted Fast Track review status for prevention of hemodialysis access failure in ESRD patients

9 Feb 2011
CytRx's bafetinib helps reduce skeletal complications in cancer patients

CytRx's bafetinib helps reduce skeletal complications in cancer patients

8 Feb 2011
Rib-X commences Phase 2b trial to assess delafloxacin, linezolid, vancomycin for treatment of ABSSSI

Rib-X commences Phase 2b trial to assess delafloxacin, linezolid, vancomycin for treatment of ABSSSI

8 Feb 2011
Ansaris receives milestone payment for identification of kinase-related compound for cancer, autoimmune diseases

Ansaris receives milestone payment for identification of kinase-related compound for cancer, autoimmune diseases

8 Feb 2011
Elan 2010 total revenue increases 5% to $1,169.7 million

Elan 2010 total revenue increases 5% to $1,169.7 million

8 Feb 2011
U.S. FDA orders three TMJ implant manufacturers to conduct postmarket surveillance studies

U.S. FDA orders three TMJ implant manufacturers to conduct postmarket surveillance studies

8 Feb 2011
Cleveland Clinic, JumpStart Ventures invest $500,000 in SironRX Therapeutics

Cleveland Clinic, JumpStart Ventures invest $500,000 in SironRX Therapeutics

8 Feb 2011
Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

Transition reports second quarter 2011 net income of $24.28M vs. $6.05M net loss for second quarter 2010

8 Feb 2011
PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

PharmaMar initiates PM060184 Phase I clinical trial in patients with solid tumors

7 Feb 2011
USPTO issues key patent to ISTO's NuQu product for degenerative disc disease treatment

USPTO issues key patent to ISTO's NuQu product for degenerative disc disease treatment

7 Feb 2011
AMRI fourth quarter total revenue increases 12% to $48.6 million

AMRI fourth quarter total revenue increases 12% to $48.6 million

7 Feb 2011
EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

EntreMed announces publication of ENMD-2076 Phase 1 results against solid tumors in AACR journal

4 Feb 2011
UofL receives $9.56 million NIH/NHLBI grant to study cardioprotective therapies

UofL receives $9.56 million NIH/NHLBI grant to study cardioprotective therapies

4 Feb 2011
JDRF, Eli Lilly sign agreement to fund type 1 diabetes research for re-generative medicine

JDRF, Eli Lilly sign agreement to fund type 1 diabetes research for re-generative medicine

4 Feb 2011
Nitto Denko announces acquisition of Avecia Biotechnology

Nitto Denko announces acquisition of Avecia Biotechnology

3 Feb 2011
AVEO receives USAN, WHO generic name approval for ficlatuzumab

AVEO receives USAN, WHO generic name approval for ficlatuzumab

3 Feb 2011
Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

Concert and WRAIR enter CRADA to evaluate novel compound for seizure protection associated with TBI

3 Feb 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback